Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1986-11-24
|
pubmed:abstractText |
We observed that after KMT-17 cells had been treated with bleomycin (BLM), even with a dose as high as 160 micrograms/ml, they were still able to form colonies in soft agar. We then studied the susceptibility of KMT-17 cells treated with BLM to activated macrophages. During a colony inhibition assay, BLM-treated KMT-17 cells were found to be much more susceptible to activated macrophages than nontreated KMT-17 cells, moreover, a tumor neutralizing assay showed that the growth of BLM-treated KMT-17 cells was also significantly inhibited by activated macrophages as compared with nontreated KMT-17 cells. Macrophages activated by both BLM and the Nocardia rubra cell wall skeleton were able to mediate such tumor inhibition activity in BLM-treated KMT-17 cells. Activated macrophages did not seem to have strong antitumor activity against nontreated KMT-17 cells in vivo, however, the life span of the rats which were inoculated i.p. with KMT-17 cells was significantly expanded after the tumor-bearing rats were given BLM i.p. The data presented here suggest that not only does BLM have a direct tumoricidal effect on KMT-17 cells, it also regulates immunosensitivity of targets to immune effectors. We also discuss the mechanism for enhancing the susceptibility of KMT-17 cells to activated macrophages brought about by treatment with BLM.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0340-7004
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
46-50
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2429768-Animals,
pubmed-meshheading:2429768-Bleomycin,
pubmed-meshheading:2429768-Cell Line,
pubmed-meshheading:2429768-Cell Survival,
pubmed-meshheading:2429768-Injections, Intraperitoneal,
pubmed-meshheading:2429768-Macrophage Activation,
pubmed-meshheading:2429768-Macrophages,
pubmed-meshheading:2429768-Neoplasms, Experimental,
pubmed-meshheading:2429768-Peritoneal Cavity,
pubmed-meshheading:2429768-Rats,
pubmed-meshheading:2429768-Tumor Stem Cell Assay
|
pubmed:year |
1986
|
pubmed:articleTitle |
Enhanced susceptibility of target KMT-17 cells to activated macrophages by treatment with the antitumor agent bleomycin.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|